[go: up one dir, main page]

DE60016560D1 - Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) - Google Patents

Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)

Info

Publication number
DE60016560D1
DE60016560D1 DE2000616560 DE60016560T DE60016560D1 DE 60016560 D1 DE60016560 D1 DE 60016560D1 DE 2000616560 DE2000616560 DE 2000616560 DE 60016560 T DE60016560 T DE 60016560T DE 60016560 D1 DE60016560 D1 DE 60016560D1
Authority
DE
Germany
Prior art keywords
igf
muted
insulin
variant
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2000616560
Other languages
English (en)
Other versions
DE60016560T2 (de
Inventor
Yves Dubaquie
Paul J Fielder
Henry B Lowman
Deborah L Mortensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE60016560D1 publication Critical patent/DE60016560D1/de
Application granted granted Critical
Publication of DE60016560T2 publication Critical patent/DE60016560T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60016560T 1999-01-06 2000-01-05 Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) Expired - Lifetime DE60016560T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06
US115010P 1999-01-06
US17026199P 1999-12-09 1999-12-09
US170261P 1999-12-09
PCT/US2000/000199 WO2000040613A1 (en) 1999-01-06 2000-01-05 Insulin-like growth factor (igf) i mutant variants

Publications (2)

Publication Number Publication Date
DE60016560D1 true DE60016560D1 (de) 2005-01-13
DE60016560T2 DE60016560T2 (de) 2005-12-15

Family

ID=26812755

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016560T Expired - Lifetime DE60016560T2 (de) 1999-01-06 2000-01-05 Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)

Country Status (12)

Country Link
US (3) US6403764B1 (de)
EP (1) EP1141014B1 (de)
JP (2) JP3971108B2 (de)
AT (1) ATE284415T1 (de)
AU (1) AU762351B2 (de)
CA (1) CA2356109C (de)
DE (1) DE60016560T2 (de)
DK (1) DK1141014T3 (de)
ES (1) ES2234560T3 (de)
IL (2) IL143866A0 (de)
PT (1) PT1141014E (de)
WO (1) WO2000040613A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
US20020143725A1 (en) * 2001-01-29 2002-10-03 Smith Robin Young Systems, methods and computer program products for determining parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby
US7250950B2 (en) * 2001-01-29 2007-07-31 Symyx Technologies, Inc. Systems, methods and computer program products for determining parameters for chemical synthesis
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1674113A1 (de) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
EP1838736B1 (de) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto-bindende moleküle
JP4988599B2 (ja) * 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
ES2393373T3 (es) * 2006-08-31 2012-12-20 F. Hoffmann-La Roche Ag Método para la producción de factor-I de crecimiento similar a la insulina
HUE025408T2 (hu) 2007-01-25 2016-02-29 Hoffmann La Roche IGFBP-7 alkalmazása szívelégtelenség megítélésében
CA2679548C (en) * 2007-03-02 2015-01-27 Amgen Inc. Methods and compositions for treating tumor diseases
AU2008262387A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology IGF for the treatment of Rett Syndrome and synaptic disorders
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
RU2010144014A (ru) * 2008-04-03 2012-05-27 Ф. Хоффманн-Ля Рош Аг (Ch) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CN102510757B (zh) * 2009-07-22 2015-03-18 益普生制药股份有限公司 在第59位置处具有氨基酸替换的胰岛素样生长因子-1(igf-1)类似物
BR112012005485A2 (pt) 2009-09-10 2016-04-19 Lonza Biologics Plc método e sistema para a purificação de polipeptídeo
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
KR20140002601A (ko) 2010-07-09 2014-01-08 바이오겐 이데크 헤모필리아 인코포레이티드 키메라 응고 인자
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EA201491346A1 (ru) 2012-01-10 2014-11-28 Байоджен Айдек Ма Инк. Усиление транспорта терапевтических молекул через гематоэнцефалический барьер
SI2935320T1 (sl) 2012-12-18 2019-12-31 Novartis Ag Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
CN104293766A (zh) * 2013-07-15 2015-01-21 四川农业大学 山羊IGFBP3基因cDNA编码序列克隆的方法
CN105792839A (zh) 2013-10-02 2016-07-20 诺华股份有限公司 用于治疗的胰岛素样生长因子拟似物
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
CN116987172A (zh) 2014-01-20 2023-11-03 韩美药品株式会社 长效胰岛素及其用途
EP3100056A2 (de) 2014-01-27 2016-12-07 Novartis AG Biomarker zur prädiktion von muskelatrophie, verfahren und verwendung
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
JP6772156B2 (ja) 2015-02-04 2020-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 治療用分子を選択する方法
UY36550A (es) 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN110546161B (zh) 2016-09-23 2024-01-26 韩美药品股份有限公司 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途
JP7604098B2 (ja) 2017-03-23 2024-12-23 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途
CN117384275B (zh) * 2023-12-13 2024-03-15 北京科为博生物科技有限公司 胰岛素样生长因子突变体igf1m及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
JP2648951B2 (ja) 1987-04-06 1997-09-03 セルトリックス ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
ATE109828T1 (de) 1987-04-23 1994-08-15 Monsanto Co Sekretion eines dem insulin ähnlichen wachstumsfaktors in e. coli.
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
WO1989005822A1 (en) * 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
EP0327503B1 (de) 1988-02-05 1993-03-10 Ciba-Geigy Ag Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
WO1989009792A1 (en) 1988-04-12 1989-10-19 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
NZ253867A (en) 1992-06-12 1996-08-27 Cephalon Inc Treating peripheral neuropathy using igf-1 or igf-3
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
DE59305396D1 (de) 1992-12-02 1997-03-20 Hoechst Ag Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
EP0642350A4 (de) 1993-01-25 1995-06-28 Beth Israel Hospital Methode zur modifizierung, diagnose und dem aufspüren von igf-1 sensitiven zellbarriereeigenschaften.
CA2154078A1 (en) 1993-01-29 1994-08-04 George N. Cox Wound healing composition
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
HU221092B1 (en) 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
HU224345B1 (hu) 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
US5728676A (en) 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
AU697119B2 (en) 1995-05-26 1998-09-24 Theratechnologies Inc. Chimeric fatty body-pro-GRF analogs with increased biological potency
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
IL122102A (en) 1995-06-07 2002-07-25 Glaxo Group Ltd Peptides and compounds that bind to a thrombopoietin receptor, pharmaceutical compositions comprising them and their use as medicaments
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
AU2676297A (en) 1996-04-17 1997-11-07 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
AR048563A1 (es) 1996-09-16 2006-05-10 Univ Dalhousie Metodos para el tratamiento de la enfermedad renal poliquistica en un mamifero, la insuficiencia renal, el desarrollo glomerular y de los rinones y proteger de la toxicidad por hormonas esteroides y uso de la igf- i para la fabricacion de una composicion farmaceutica.
IL129772A0 (en) 1996-11-06 2000-02-29 Genentech Inc Constrained helical peptides and methods of making same
WO1998029451A1 (fr) 1996-12-27 1998-07-09 Daiichi Pharmaceutical Co., Ltd. Procede pour elever la concentration de facteur de croissance libre apparente a l'insuline
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
WO1999051262A2 (en) 1998-04-03 1999-10-14 Chiron Corporation Use of igfi for treating articular cartilage disorders
WO2000020023A2 (en) 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Null igf for the treatment of cancer
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
EP2043676A2 (de) 2006-07-06 2009-04-08 Molecular Logix, Inc. Rezeptorantagonisten des insulinähnlichen wachstumsfaktors 1

Also Published As

Publication number Publication date
US7105167B2 (en) 2006-09-12
US6403764B1 (en) 2002-06-11
US20110003746A1 (en) 2011-01-06
WO2000040613A9 (en) 2001-05-17
JP2006328074A (ja) 2006-12-07
JP3971108B2 (ja) 2007-09-05
ES2234560T3 (es) 2005-07-01
CA2356109C (en) 2008-04-22
AU762351B2 (en) 2003-06-26
DK1141014T3 (da) 2005-04-11
US20020160955A1 (en) 2002-10-31
DE60016560T2 (de) 2005-12-15
EP1141014B1 (de) 2004-12-08
IL143866A0 (en) 2002-04-21
AU2224500A (en) 2000-07-24
US8097587B2 (en) 2012-01-17
IL143866A (en) 2009-11-18
ATE284415T1 (de) 2004-12-15
JP2002535968A (ja) 2002-10-29
CA2356109A1 (en) 2000-07-13
EP1141014A1 (de) 2001-10-10
PT1141014E (pt) 2005-04-29
WO2000040613A1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
DE60016560D1 (de) Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ATE335813T1 (de) Protease varianten
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
AU4415899A (en) Alpha-keto oxadiazoles as serine protease inhibitors
ZA992445B (en) Benzoxazinones/benzothiazinones as serine protease inhibitors.
MXPA02012206A (es) Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
DE60143606D1 (de) Xylanase-varianten mit veränderter sensitivität gegenüber xylanase-hemmstoffen
PL347948A1 (en) Serine protease inhibitor
NO961067D0 (no) Subtilisin BPN' varianter med senket adsorpsjon og öket hydrolyse
NO20025893D0 (no) Veksthormon sekretagoga
IL149005A0 (en) Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
DK1273299T3 (da) Minoxidilinindeholdende praparater
ZA971733B (en) Serine protease inhibitors.
GB9917909D0 (en) Cysteine protease inhibitors
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
EP1179052A4 (de) Serinproteasen
BG106316A (en) Ambroxol-containing lozenge
ATE267863T1 (de) Flüssige entkalkungs-zusammensetzung
ZA200107081B (en) Lyophilisates with improved reconstitutibility.
AP2000001945A0 (en) Leishmania cysteine proteinases.
AU1730797A (en) 3-substituted-4-oxa-1-azabicyclo{3,2,0}heptan-7-one as cysteine protease inhibitors
BR9710965A (pt) Detergentes contendo enzima protease e enzima loccase
AU6407701A (en) Serine protease inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition